Healthcare Industry News: Tendyne
News Release - December 10, 2014
Jean Boulle Group Announces Successful First Human Implants of the Nickel-Titanium Tendyne Transcatheter Mitral Valve
LUXEMBOURG, Dec. 10, 2014 -- (Healthcare Sales & Marketing Network) -- Boulle Medtech Ltd., a Jean Boulle Group private company focusing on medical technology, and founding investor of Tendyne Holdings, Inc. ("Tendyne"), is pleased to announce that Tendyne's Transcatheter Mitral Valve device has been successfully implanted in three patients. The procedures are the first in a series to be performed at various hospitals worldwide. Tendyne reports that the patients had severe mitral regurgitation that was eliminated after the procedure was performed via a trans-apical approach without cardio-pulmonary bypass (known as a trans-catheter mitral valve implantation, or "TMVI"). These first three procedures were conducted at the Royal Brompton Hospital in London, England by Dr. Neil Moat, a leading expert in mitral valve and trans-catheter mitral valve implantation. Tendyne further reports that all three patients had no major in-hospital complications and have been discharged from hospital.For more information contact Audrey Richardson at +352-222-512, audrey@jeanboullegroup.com, or go to our website http://www.jeanboullegroup.com
Source: Jean Boulle Group
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
